
    
      In this first in human, phase 1, randomized, double-blind, placebo-controlled study, single
      and multiple ascending doses of ANX009 or placebo will be administered to 48 healthy
      subjects.

      Single Ascending Dose (SAD): Each SAD subject will participate for approximately 4 weeks (3
      nights in-clinic confinement).

      Multiple Ascending Dose: Each MAD subject will participate for approximately 6 weeks (17
      nights in-clinic confinement).

      All subjects will be contacted (in clinic visit or phone call) 6 months after study
      completion.
    
  